Global ETD Search

1	Možnosti změn modelu kompenzace struktury rizika pojistného kmene s cílem posílení konkurence zdravotních pojišťoven na Slovensku / Improvement of Risk Adjustment Model to Strengthen the Competition among Health Insurance Companies in Slovakia Chochláčová, Barbora January 2018 (has links) As it is in many other sectors also in case of health insurance companies it is crucial to ensure sufficient competition what at the same reduces undesired adverse selection of enrollees. Therefore, the key is to have risk adjustment model that accurately captures future health care costs of individuals. PCG model currently used in Slovakia works apart from the simple demographic characteristics of the population as predictors also with chronic conditions. The main aim of the thesis is to compare this model in the form applied today with its modifications classifying more potentially chronic patients into the group, focusing on Hypercholesterolemia. We find a potential for improvement of the model in its adjusted versions bringing better results as from the profit/loss point of view so from R2 increase. While the implementation of the suggested models into the system is not practically limited by the availability of the necessary information nor the time or financial demand.
2	Impact of a Specialty Pharmacy-Based Oral Chemotherapy Adherence Program on Patient Adherence Russell, Kathy, Slack, Marion, Cooley, Janet, Mathews, Kelly January 2016 (has links) Class of 2016 Abstract / Objectives: Patient medication adherence is a basic requirement for treating chronic myelogenous leukemia (CML) with oral tyrosine kinase inhibitors (TKIs). When imatinib adherence rates are less than 80 or 90 percent, major and complete molecular responses, respectively, do not happen. The purpose of this study was to determine the effect of a real-time medication monitoring (RTMM) reminder system adherence program on the medication possession ratio (MPR). Methods: This analytic study was a retrospective cohort study and used data extracted from chart reviews for patients who received services from 2011 to 2015. It was approved by the Institutional Review Board. The study consisted of an intervention group and a control group (50 patients each). MPRs, demographic, descriptive, and categorical variables were summarized using means, standard deviations (SD), and frequencies/percentages. Results: The study population consisted of adult patients (mean age=62.2, SD=2.7, 50% male) treated by Avella Specialty Pharmacy who received imatinib or nilotinib as treatment for CML, gastrointestinal stromal tumors (GIST), or a similar positive Philadelphia chromosome cancer. Only 4% of patients in the intervention group had an < 85% MPR, compared to 46% in the control group (p < 0.001). Conclusions: In those patients who had an MPR of ≥ 85%, the difference between the groups was statistically significant. As past studies have shown, adherence rates greater than 90% have a higher likelihood of a major or complete molecular response and a greatly reduced risk of disease progression. pharmacy-based oral chemotherapy patient adherence chronic myelogenous leukemia (CML) oral tyrosine kinase inhibitors (TKIs) real-time medication monitoring (RTMM)
3	Pharmacist Utilization of Opioid Misuse and Abuse Interventions: Acceptability Among Pharmacists and Patients in Detox Beechey Riley, Tegan Anne 14 July 2017 (has links) No description available. Pharmacy Sciences Public Health Education Public Policy opioid opiate substance misuse substance use disorder substance abuse pharmacist patient PDMP PMP patient counseling treatment referral OTC naloxone dispensing naloxone pharmacy-based interventions misuse addiction overdose prevention

1

Page generated in 0.0454 seconds